OLAPARIB + Single agent chemotherapy
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Trial Timeline
Feb 6, 2015 → Jul 19, 2022
NCT ID
NCT02282020About OLAPARIB + Single agent chemotherapy
OLAPARIB + Single agent chemotherapy is a phase 3 stage product being developed by AstraZeneca for Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity. The current trial status is completed. This product is registered under clinical trial identifier NCT02282020. Target conditions include Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02282020 | Phase 3 | Completed |
Competing Products
20 competing products in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity